Product Information
GLIPIZIDE 5 MG TABLET is a generic product labeled by ANI Pharmaceuticals, Inc., priced at $0.0339 per EA under NDC 62559031510. Its NADAC has been published 208 times since Oct 12, 2022.
FDA first approved this application on Aug 31, 1995. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
ANI Pharmaceuticals, Inc.NDC
62559031510
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
GLIPIZIDEApproval Type
Generic (ANDA)
FDA Application
ANDA074497FDA Approved
8/31/1995
TE Code
AB
On Market Since
5/31/2022
Pharmacological Classes
Price Statistics
The NADAC for GLIPIZIDE 5 MG TABLET has been published 208 times since Oct 12, 2022, and over the history we have for it it has declined 3.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0339 per EA |
|---|---|
| All-time high | $0.0363 (Dec 13, 2023) |
| All-time low | $0.0252 (Nov 20, 2024) |
| 52-week high | $0.0360 |
| 52-week low | $0.0339 |
| Median price | $0.0345 |
| Average price | $0.0340 |
| Largest weekly change | -26.1% (Nov 20, 2024) |
| Weeks tracked | 208 |
| Tracking since | Oct 12, 2022 |
Generic Alternatives
The matcher finds 11 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
ANI Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Glipizide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Sulfonylurea class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GLIPIZIDE 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for GLIPIZIDE 5 MG TABLET, manufactured by ANI Pharmaceuticals, Inc., is $0.0339 per EA (NDC 62559031510), effective Sep 30, 2026.
How has the price of GLIPIZIDE 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for GLIPIZIDE 5 MG TABLET has declined 3.6%. It has been tracked across 208 weekly CMS publications since Oct 12, 2022.
What are the highest and lowest recorded NADAC prices for GLIPIZIDE 5 MG TABLET?
Since Oct 12, 2022, the NADAC for GLIPIZIDE 5 MG TABLET has ranged from a low of $0.0252 (Nov 20, 2024) to a high of $0.0363 (Dec 13, 2023), with a median of $0.0345 per EA.
Are there cheaper alternatives to GLIPIZIDE 5 MG TABLET?
11 manufacturers publish a NADAC-priced product with the same active ingredient and strength as GLIPIZIDE 5 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures GLIPIZIDE 5 MG TABLET?
GLIPIZIDE 5 MG TABLET (NDC 62559031510) is labeled by ANI Pharmaceuticals, Inc., and CMS classifies it as a generic product.